K010287

Substantially Equivalent

SCIMEDX PHASE II PR3 IGG ANTIBODY EIA

Applicant: Scimedx Corp.
Product code: MOB
Advisory panel: Immunology
Date received: 2001-01-31
Decision date: 2001-03-16
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Denvill, NJ, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.